The company said it has received the final approval from the US Food and Drug Administration (USFDA) to market the product in multiple strengths.from Moneycontrol Business News https://ift.tt/GvUHmsR
Subscribe to:
Post Comments (Atom)
LTIMindtree Q4 Preview: Lower pass-through revenue seen impacting growth marginally
A compilation of estimates suggests the company#39;s Q4 FY24 net profit is projected to decline by 2.2 percent quarter on quarter to Rs 1,1...
-
At an online engagement with the creditors, the government on Friday said that assurances from bilateral creditors are required as a prereq...
-
In a regulatory filing the company said the Odisha Electricity Regulatory Commission (OERC) has awarded the Letter of Intent (LOI) to Tata ...
No comments:
Post a Comment